BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Axatilimab readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Axatilimab\, from ClinicalTrials.gov esti
 mates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05723055-3003@assetmemo.bio
DTSTAMP:20261121T005621Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Axatilimab: Phase 2 readout est. (NCT05723055)
DESCRIPTION:Axatilimab\, phase 2.\nStudy: Evaluating Combination of Nivolum
 ab and Axatilimab in Patients With Relapsed/Refractory Classical Hodgkin L
 ymphoma\nEstimated primary completion: December 2026. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/axatilimab#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT05723055
URL:https://assetmemo.bio/drug/axatilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05491226-3003@assetmemo.bio
DTSTAMP:20261121T005621Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Axatilimab: Phase 2 readout est. (NCT05491226)
DESCRIPTION:Axatilimab\, phase 2.\nStudy: Reinvigorating TNBC Response to I
 mmunotherapy With Combination Myeloid Inhibition and Radiation\nEstimated 
 primary completion: 1 December 2026. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/axatilimab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT05491226
URL:https://assetmemo.bio/drug/axatilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06843408-3003@assetmemo.bio
DTSTAMP:20261121T005621Z
DTSTART;VALUE=DATE:20270106
DTEND;VALUE=DATE:20270107
SUMMARY:Axatilimab: Phase 1/2 readout est. (NCT06843408)
DESCRIPTION:Axatilimab\, phase 1/2\, Chronic Graft-versus-Host Disease.\nSt
 udy: A Ph1b/2 Study of Axatilimab Monotherapy in Chinese Participants With
  Recurrent or Refractory cGVHD\nEstimated primary completion: 6 January 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/axatilimab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT06843408
URL:https://assetmemo.bio/drug/axatilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06320405-3003@assetmemo.bio
DTSTAMP:20261121T005621Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Axatilimab: Phase 1/2 readout est. (NCT06320405)
DESCRIPTION:Axatilimab\, phase 1/2.\nStudy: Axatilimab in Combination With 
 Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced or
  Metastatic Solid Tumors\nEstimated primary completion: 1 April 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/axatilimab#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06320405
URL:https://assetmemo.bio/drug/axatilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06488378-3003@assetmemo.bio
DTSTAMP:20261121T005621Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:Axatilimab: Phase 1 readout est. (NCT06488378)
DESCRIPTION:Axatilimab\, phase 1.\nStudy: Phase Ib Study of Axatilimab in C
 ombination With Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-
 negative Breast Cancer\nEstimated primary completion: 1 May 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/axatilimab#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT06488378
URL:https://assetmemo.bio/drug/axatilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06585774-3003@assetmemo.bio
DTSTAMP:20261121T005621Z
DTSTART;VALUE=DATE:20270928
DTEND;VALUE=DATE:20270929
SUMMARY:Axatilimab: Phase 3 readout est. (NCT06585774)
DESCRIPTION:Axatilimab\, phase 3\, Chronic Graft-versus-Host Disease.\nStud
 y: A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment
  for Chronic Graft-Versus-Host Disease\nEstimated primary completion: 28 S
 eptember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/axatil
 imab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T06585774
URL:https://assetmemo.bio/drug/axatilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06523556-3003@assetmemo.bio
DTSTAMP:20261121T005621Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Axatilimab: Phase 1/2 readout est. (NCT06523556)
DESCRIPTION:Axatilimab\, phase 1/2.\nStudy: Axatilimab With or Without Azac
 itidine for the Treatment of Patients With Advanced Phase Myeloproliferati
 ve Neoplasms\, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overla
 p or High Risk Chronic Myelomonocytic Leukemia\nEstimated primary completi
 on: 31 October 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 axatilimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06523556
URL:https://assetmemo.bio/drug/axatilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06821542-3003@assetmemo.bio
DTSTAMP:20261121T005621Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Axatilimab: Phase 3 readout est. (NCT06821542)
DESCRIPTION:Axatilimab\, phase 3\, Chronic Graft-versus-Host Disease.\nStud
 y: A Study to Evaluate Axatilimab Versus Best Available Therapy in Partici
 pants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines 
 of Systemic Therapy\nEstimated primary completion: 31 May 2028. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/axatilimab#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT06821542
URL:https://assetmemo.bio/drug/axatilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07011810-3003@assetmemo.bio
DTSTAMP:20261121T005621Z
DTSTART;VALUE=DATE:20280810
DTEND;VALUE=DATE:20280811
SUMMARY:Axatilimab: Phase 2 readout est. (NCT07011810)
DESCRIPTION:Axatilimab\, phase 2\, Chronic Graft-versus-Host Disease.\nStud
 y: Axatilimab for Sclerotic Chronic Graft-versus-Host Disease\nEstimated p
 rimary completion: 10 August 2028. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/axatilimab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07011810
URL:https://assetmemo.bio/drug/axatilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07638982-3003@assetmemo.bio
DTSTAMP:20261121T005621Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Axatilimab: Phase 1 readout est. (NCT07638982)
DESCRIPTION:Axatilimab\, phase 1.\nStudy: Axatilimab + CAR-T for High-Risk 
 Lymphoma\nEstimated primary completion: 31 December 2028. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/axatilimab#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07638982
URL:https://assetmemo.bio/drug/axatilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07124078-3003@assetmemo.bio
DTSTAMP:20261121T005621Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Axatilimab: Phase 2 readout est. (NCT07124078)
DESCRIPTION:Axatilimab\, phase 2\, Chronic Graft-versus-Host Disease.\nStud
 y: A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatr
 ic Participants With Chronic Graft-Versus-Host Disease After at Least 2 Pr
 ior Lines of Systemic Therapy (AGAVE-256)\nEstimated primary completion: 3
 1 January 2029. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/axati
 limab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07124078
URL:https://assetmemo.bio/drug/axatilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07511062-3003@assetmemo.bio
DTSTAMP:20261121T005621Z
DTSTART;VALUE=DATE:20290801
DTEND;VALUE=DATE:20290802
SUMMARY:Axatilimab: Phase 1 readout est. (NCT07511062)
DESCRIPTION:Axatilimab\, phase 1.\nStudy: Axatilimab Combined With Decitabi
 ne/Venetoclax for the Treatment of TP53-mutated AML\nEstimated primary com
 pletion: 1 August 2029. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/axatilimab#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07511062
URL:https://assetmemo.bio/drug/axatilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06663722-3003@assetmemo.bio
DTSTAMP:20261121T005621Z
DTSTART;VALUE=DATE:20300505
DTEND;VALUE=DATE:20300506
SUMMARY:Axatilimab: Phase 2 readout est. (NCT06663722)
DESCRIPTION:Axatilimab\, phase 2\, Chronic Graft-versus-Host Disease.\nStud
 y: Axatilimab in Combination With Extracorporeal Photopheresis (ECP) in Ch
 ronic Graft-versus-Host Disease\nEstimated primary completion: 5 May 2030.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/axatilimab#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06663722
URL:https://assetmemo.bio/drug/axatilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07128381-3003@assetmemo.bio
DTSTAMP:20261121T005621Z
DTSTART;VALUE=DATE:20310731
DTEND;VALUE=DATE:20310801
SUMMARY:Axatilimab: Phase 1/2 readout est. (NCT07128381)
DESCRIPTION:Axatilimab\, phase 1/2.\nStudy: Phase I/II Clinical Trial of Ax
 atilimab\, a CSF1R Monoclonal Antibody\, in Combination With Ruxolitinib a
 s Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic 
 Leukemia (CMML)\nEstimated primary completion: 31 July 2031. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/axatilimab#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07128381
URL:https://assetmemo.bio/drug/axatilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07808112-3003@assetmemo.bio
DTSTAMP:20261121T005621Z
DTSTART;VALUE=DATE:20311130
DTEND;VALUE=DATE:20311201
SUMMARY:Axatilimab: Phase 2 readout est. (NCT07808112)
DESCRIPTION:Axatilimab\, phase 2.\nStudy: CSF-1R Inhibitor\, Axatilimab\, f
 or Prevention of Acute and Chronic GVHD After HLA-Matched Related and Unre
 lated Donor Allogeneic Stem Cell Transplantation\nEstimated primary comple
 tion: November 2031. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 axatilimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07808112
URL:https://assetmemo.bio/drug/axatilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07015853-3003@assetmemo.bio
DTSTAMP:20261121T005621Z
DTSTART;VALUE=DATE:20331231
DTEND;VALUE=DATE:20340101
SUMMARY:Axatilimab: Phase 2 readout est. (NCT07015853)
DESCRIPTION:Axatilimab\, phase 2.\nStudy: ASTRAEA: ReinvigorAting ReSponse 
 To ImmunotheRApy in MEtAstatic TNBC With Combination Myeloid Inhibition an
 d Radiation\nEstimated primary completion: December 2033. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/axatilimab#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07015853
URL:https://assetmemo.bio/drug/axatilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
